BOSTON / Aug 06, 2024 / Business Wire / 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarter ended June 30, 2024.
"We delivered solid execution on a multitude of fronts in the quarter, including the acquisition and integration of RedWave Technology into our company. With an expanded handheld portfolio, we are now supporting both our new and existing forensics customers more efficiently,” said Kevin J. Knopp, CEO and Co-founder. “We also maintained a strong focus on operational excellence during the quarter and have begun to see early benefits of our increasing scale.”
Recent Highlights
Second Quarter 2024 Financial Results
Revenue was $14.0 million for the three months ended June 30, 2024, a 16% increase over the prior year period. This was primarily driven by an increase in handheld devices revenue offset by a decrease in desktop devices revenue. The installed base grew to 3,067 devices with 143 handheld devices and 10 desktop devices placed during the second quarter 2024. Recurring revenue represented 38% of total revenues in the quarter.
Gross profit was $7.4 million for the second quarter of 2024, compared to $5.8 million for the corresponding period in the prior year. Gross margin was 53% as compared to 48% for the corresponding prior year period. Adjusted gross profit was $8.1 million for the second quarter of 2024, compared to $6.0 million for the corresponding period in the prior year. Adjusted gross margin was 58% as compared to 50% for the corresponding prior year period.
Operating expenses were $21.0 million for the second quarter of 2024, compared to $16.7 million for the corresponding prior year period. This increase was driven by $1.9 million in acquisition and integration costs, the inclusion of two months of operating expenses related to our RedWave acquisition, and stock-based compensation.
Net loss was $12.5 million for the second quarter of 2024, compared to $9.3 million for the corresponding prior year period. Adjusted EBITDA was a loss of $7.3 million for the second quarter of 2024, compared to a loss of $7.7 million for the second quarter of 2023.
Cash, cash equivalents and marketable securities were $77.4 million as of June 30, 2024 with no debt outstanding.
2024 Guidance
908 Devices continues to expect full year reported 2024 revenue to be in the range of $63.0 million to $65.0 million, representing 25% to 29% growth over full year 2023. This includes $11 million of expected revenue from RedWave Technology, representing 8 months of ownership.
Webcast Information
908 Devices will host a conference call to discuss the second quarter 2024 financial results before market open on Tuesday, August 6, 2024 at 5:30 am Pacific Time / 8:30 am Eastern Time. A webcast of the conference call can be accessed at https://ir.908devices.com/news-events/events. The webcast will be archived and available for replay for at least 90 days after the event.
About 908 Devices
908 Devices is revolutionizing chemical analysis with its simple handheld and desktop devices, addressing life-altering applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in forensics, bioprocessing, pharma / biopharma, life sciences research and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of complementary analytical technologies, microfluidic sampling and separations, software automation, and machine learning.
Non-GAAP Measures of Financial Performance
To supplement the Company’s financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included in this release and presented with detailed reconciliations to comparable GAAP financial results in the tables below:
The Company’s non-GAAP financial results presented in this earnings release exclude certain costs that management believes do not have a direct correlation to future business operations, nor do the resulting charges recorded accurately reflect the performance of ongoing operations for the period in which such charges are recorded, nor do the resulting charges recorded accurately reflect the anticipated cash flows of ongoing operations, and as such, excluding these costs allows management to understand and evaluate core operating performance and trends. However, as there are no standardized methods of calculating these non-GAAP financial measures, the Company’s methods may differ from those used by other companies in its industry, and accordingly, the use of these measures may not be directly comparable to similar measures used by others, thus limiting their usefulness for purposes of comparison. Furthermore, these non-GAAP measures have certain limitations since they do not include the impact of certain expenses and cash flows that are reflected in the Company’s GAAP financial results. Accordingly, when analyzing the Company’s operating performance and guidance, investors should not consider non-GAAP measures in isolation or as a substitute for, or superior to, comparable financial measures prepared in accordance with GAAP. Rather, the Company believes that these non-GAAP financial measures, when viewed in addition to and not in lieu of reported GAAP financial results, provide investors with additional meaningful information to assess financial performance and trends, enable comparison of financial results between periods, and allow for greater transparency with respect to key metrics utilized internally in analyzing and operating the Company’s business.
Forward Looking Statements
This press release includes “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the Company’s future revenue and growth. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission which are available on the SEC's website at www.sec.gov. Additional information will be made available in our annual and quarterly reports and other filings that we make from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.
908 DEVICES INC.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share amounts)
(unaudited)
|
| Three Months Ended |
| Six Months Ended | ||||||||||||
|
| June 30, |
| June 30, | ||||||||||||
|
| 2024 |
| 2023 |
| 2024 |
| 2023 | ||||||||
Revenue: |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Product revenue |
| $ | 10,266 |
|
| $ | 9,595 |
|
| $ | 17,499 |
|
| $ | 16,617 |
|
Service revenue |
|
| 3,681 |
|
|
| 2,354 |
|
|
| 6,439 |
|
|
| 4,594 |
|
Contract revenue |
|
| 100 |
|
|
| 145 |
|
|
| 100 |
|
|
| 370 |
|
Total revenue |
|
| 14,047 |
|
|
| 12,094 |
|
|
| 24,038 |
|
|
| 21,581 |
|
Cost of revenue: |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Product cost of revenue |
|
| 4,732 |
|
|
| 4,800 |
|
|
| 7,942 |
|
|
| 8,586 |
|
Service cost of revenue |
|
| 1,823 |
|
|
| 1,448 |
|
|
| 3,601 |
|
|
| 2,718 |
|
Contract cost of revenue |
|
| 74 |
|
|
| 52 |
|
|
| 74 |
|
|
| 99 |
|
Total cost of revenue |
|
| 6,629 |
|
|
| 6,300 |
|
|
| 11,617 |
|
|
| 11,403 |
|
Gross profit |
|
| 7,418 |
|
|
| 5,794 |
|
|
| 12,421 |
|
|
| 10,178 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Research and development |
|
| 6,381 |
|
|
| 5,525 |
|
|
| 12,171 |
|
|
| 10,923 |
|
Selling, general and administrative |
|
| 14,597 |
|
|
| 11,208 |
|
|
| 26,498 |
|
|
| 23,211 |
|
Total operating expenses |
|
| 20,978 |
|
|
| 16,733 |
|
|
| 38,669 |
|
|
| 34,134 |
|
Loss from operations |
|
| (13,560 | ) |
|
| (10,939 | ) |
|
| (26,248 | ) |
|
| (23,956 | ) |
Other income, net |
|
| 943 |
|
|
| 1,522 |
|
|
| 2,644 |
|
|
| 1,955 |
|
Loss from operations before income taxes |
|
| (12,617 | ) |
|
| (9,417 | ) |
|
| (23,604 | ) |
|
| (22,001 | ) |
Benefit for income taxes |
|
| 69 |
|
|
| 71 |
|
|
| 139 |
|
|
| 122 |
|
Net loss |
| $ | (12,548 | ) |
| $ | (9,346 | ) |
| $ | (23,465 | ) |
| $ | (21,879 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Net loss per share attributable to common stockholders |
| $ | (0.37 | ) |
| $ | (0.29 | ) |
| $ | (0.70 | ) |
| $ | (0.68 | ) |
Weighted average common shares outstanding |
|
| 34,061,933 |
|
|
| 32,199,156 |
|
|
| 33,386,413 |
|
|
| 32,083,122 |
|
908 DEVICES INC.
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)
|
| June 30, |
| December 31, | ||
|
| 2024 |
| 2023 | ||
Assets |
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
Cash, cash equivalents and marketable securities |
| $ | 77,383 |
| $ | 145,682 |
Accounts receivable, net |
|
| 10,987 |
|
| 8,989 |
Inventory |
|
| 18,589 |
|
| 14,938 |
Prepaid expenses and other current assets |
|
| 3,485 |
|
| 4,181 |
Total current assets |
|
| 110,444 |
|
| 173,790 |
Operating lease, right-of-use assets |
|
| 5,904 |
|
| 6,233 |
Property and equipment, net |
|
| 3,556 |
|
| 3,342 |
Goodwill |
|
| 40,220 |
|
| 10,367 |
Intangible, net |
|
| 47,298 |
|
| 7,860 |
Other long-term assets |
|
| 1,352 |
|
| 1,389 |
Total assets |
| $ | 208,774 |
| $ | 202,981 |
Liabilities and Stockholders' Equity |
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
Accounts payable and accrued expenses |
| $ | 7,610 |
| $ | 9,904 |
Deferred revenue |
|
| 11,954 |
|
| 10,629 |
Operating lease liabilities |
|
| 2,153 |
|
| 2,016 |
Total current liabilities |
|
| 21,717 |
|
| 22,549 |
Deferred revenue, net of current portion |
|
| 9,528 |
|
| 3,929 |
Other long-term liabilities |
|
| 21,170 |
|
| 11,012 |
Total liabilities |
|
| 52,415 |
|
| 37,490 |
Total stockholders' equity |
|
| 156,359 |
|
| 165,491 |
Total liabilities and stockholders' equity |
| $ | 208,774 |
| $ | 202,981 |
908 DEVICES INC.
Reconciliations of GAAP to Non-GAAP Financial Measures
(Unaudited, amounts in thousands, except percentage and per share data)
In all tables below, totals may not add due to rounding
Reconciliation from Gross Profit (GAAP) to Adjusted Gross Profit (Non-GAAP) and Margin Percentage:
|
| Three Months Ended |
| Six Months Ended | ||||||||||||
|
| June 30, |
| June 30, | ||||||||||||
|
| 2024 |
| 2023 |
| 2024 |
| 2023 | ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Gross Profit (GAAP) |
| $ | 7,418 |
|
| $ | 5,794 |
|
| $ | 12,421 |
|
| $ | 10,178 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Intangible amortization |
|
| 530 |
|
|
| 107 |
|
|
| 637 |
|
|
| 213 |
|
Acquisition and integration costs |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
Restructuring |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
Stock-based compensation |
|
| 202 |
|
|
| 140 |
|
|
| 373 |
|
|
| 255 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Adjusted Gross Profit (Non-GAAP) |
| $ | 8,150 |
|
| $ | 6,041 |
|
| $ | 13,431 |
|
| $ | 10,646 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Gross Margin Percentage (GAAP) |
|
| 53 | % |
|
| 48 | % |
|
| 52 | % |
|
| 47 | % |
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Adjusted Gross Margin Percentage (Non-GAAP) |
|
| 58 | % |
|
| 50 | % |
|
| 56 | % |
|
| 49 | % |
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation from Net Loss (GAAP) to Adjusted EBITDA (Non-GAAP):
|
| Three Months Ended |
| Six Months Ended | ||||||||||||
|
| June 30, |
| June 30, | ||||||||||||
|
| 2024 |
|
| 2023 |
|
| 2024 |
|
| 2023 |
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Net Loss (GAAP) |
| $ | (12,548 | ) |
| $ | (9,346 | ) |
| $ | (23,465 | ) |
| $ | (21,879 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Other income, net |
|
| (943 | ) |
|
| (1,522 | ) |
|
| (2,644 | ) |
|
| (1,955 | ) |
Benefit for income taxes |
|
| (69 | ) |
|
| (71 | ) |
|
| (139 | ) |
|
| (122 | ) |
Depreciation |
|
| 500 |
|
|
| 368 |
|
|
| 918 |
|
|
| 738 |
|
Intangible amortization |
|
| 693 |
|
|
| 219 |
|
|
| 913 |
|
|
| 437 |
|
Acquisition and integration costs |
|
| 1,950 |
|
|
| - |
|
|
| 1,950 |
|
|
| - |
|
Restructuring |
|
| - |
|
|
| - |
|
|
| - |
|
|
| 524 |
|
Stock-based compensation |
|
| 3,096 |
|
|
| 2,578 |
|
|
| 5,739 |
|
|
| 4,744 |
|
Contingent consideration |
|
| - |
|
|
| 65 |
|
|
| - |
|
|
| 230 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Adjusted EBITDA (Non-GAAP) |
| $ | (7,321 | ) |
| $ | (7,709 | ) |
| $ | (16,728 | ) |
| $ | (17,283 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Last Trade: | US$2.06 |
Daily Change: | 0.12 6.19 |
Daily Volume: | 477,560 |
Market Cap: | US$71.730M |
December 19, 2024 November 12, 2024 April 30, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB